Table 1.
Biological, molecular and cytogenetic features of CLL patients included in the study.
Table 2.
The molecular, cytogenetic and clinical characterization of the most representative and described subsets.
Figure 1.
A: Subset #1 patients compared with all UM and M patients. B: Subset #1 compared with all non-stereotyped UM and non-stereotyped M patients. C: Subset #1 compared with all UM and M patients showing the same IGHV usage of subset #1. D and E: Subset #1 patients compared with the remaining cases grouped according to ZAP-70 and CD38 expression positivity, respectively.
Figure 2.
Subset #1 patients were compared to those positive for del(17)(13p) and del(11)(q23), and those with UM or M IGHV status.